Plasma Diacylglycerols Are Associated with Carotid Intima-Media Thickness Among Patients with Type 2 Diabetes: Findings from a Supercritical Fluid Chromatography/Mass Spectrometry-Based Semi-Targeted Lipidomic Analysis

TL;DR

This study finds that plasma diacylglycerols are linked to atherosclerosis progression in type 2 diabetes patients, as measured by carotid intima-media thickness.

Contribution

The study identifies diacylglycerols as novel lipid biomarkers associated with atherosclerosis progression in type 2 diabetes.

Findings

Ten plasma lipid species, including eight diacylglycerols, were significantly associated with CIMT in two patient groups.

22 diacylglycerols and total DG levels were significantly linked to annual CIMT progression.

Plasma DG levels improved predictive models for CIMT progression by increasing adjusted R-squared by 0.105.

Abstract

Abnormalities in plasma lipoproteins observed in patients with diabetes promote atherosclerosis. However, the association between various lipid species and classes and atherosclerosis remains unclear. Here, we aimed to identify the plasma lipid characteristics associated with atherosclerosis progression in patients with diabetes. We performed semi-targeted lipidomic analysis of fasting plasma samples using supercritical fluid chromatography coupled with mass spectrometry in two independent patient groups with type 2 diabetes (n = 223 and 31) and evaluated cross-sectional associations between plasma lipids and carotid intima-media thickness (CIMT). Ten plasma lipid species, including eight diacylglycerols (DGs), and total DG levels were significantly associated with CIMT in both groups. Patients of the former group were partly observed for 5 years, and we investigated associations between DGs and CIMT progression in these patients (n = 101). As a result, 22 DGs among the 26 identified DGs and total DG (β = 0.398, p < 0.001) were significantly associated with the annual change in CIMT. Furthermore, plasma DG levels improved the predictive ability for CIMT progression, with an adjusted R-squared increase of 0.105 [95% confidence interval: 0.010, 0.232] in the models. Plasma DGs are associated with CIMT progression in patients with type 2 diabetes. Measurement of total plasma DG levels may be beneficial in assessing the risk of atherosclerosis progression.